Inclusion Criteria:  Patients aged between 18-65 years old; Fulfilled the classification criteria of Takayasu's arteritis by ACR 1990; relapse active TAK: defined by the definition of active disease in the recommendations released by EULAR in 2018; Patients who signed the informed consent form. -  Exclusion Criteria:  Patients who failed or intolerant to either adalimumab or tofacitinib; patients with severe liver disease defined by the serum ALT or AST elevated more than 2 times the upper limits; not well controlled diabetes; uncontrolled heart failure od renal dysfunction(eGFR<30ml/min); Patients with active infection,including tuberculosis, hepatitis B and C,HIV infection, bacteria or fungal infection; upper GI bleeding 3 months before enrolement; refractory hypertension; Pregnant or intended to be pregnant 3 months after the trial; Severe coronary artery involvement demonstrated by CTA; severe cranial or cervical or renal artery diseases that need surgery; Patients that should not be included by the investigator. -